Business Context and Reporting Period
This Form 8-K reports on the 2019 Annual Meeting of Stockholders for Protalix Biotherapeutics, Inc., held on May 30, 2019. The filing was submitted on May 31, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Election of Directors: All six nominees recommended by the Board were elected. Broker non-votes totaled 37,207,180 for each nominee.
- Executive Compensation: The advisory vote on named executive officer compensation was approved with 32,204,147 votes for, 13,720,259 against, and 318,650 abstentions. Broker non-votes were 37,207,180.
- Ratification of Auditors: The appointment of Kesselman & Kesselman as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was ratified with 80,583,750 votes for, 2,236,806 against, and 629,680 abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the total number of shares entitled to vote to contextualize the high volume of broker non-votes (37,207,180) on director elections and executive compensation.
- Confirm the specific terms of the engagement with the newly ratified auditor, Kesselman & Kesselman.
- Review the full proxy statement for details on the compensation plan approved by stockholders.